

UNITAID: ACCELERATING INNOVATION IN GLOBAL HEALTH



WHO WE ARE

Unitaid brings the power of new medical discoveries to the people who most need them. Through time-limited investments, we identify the best health innovations with the potential to alleviate the burden of major diseases, and set the stage for their large-scale introduction by governments and partners such as PEPFAR, the Global Fund and WHO. Our investments result in better ways to prevent, diagnose and treat diseases including HIV/AIDS, hepatitis C, tuberculosis and malaria more quickly, affordably and effectively. A growing number of our projects address more than one disease, maximizing the effectiveness of health systems as a whole, and more than half of our portfolio is linked to antimicrobial resistance.



WHAT WE DO

Unitaid invests in grants that aim to accelerate the introduction of cutting-edge health solutions in low- and middle-income countries to accelerate the end of major diseases. For example:

- We have revolutionized childhood TB treatment with the first child-friendly TB drug, which is now benefiting children in more than 80 countries. We accelerated scale-up of a new tool that tests for drug-resistant tuberculosis, doubling the global detection rate in four years.
- Unitaid is creating a market for the first long-lasting insecticide recommended by WHO in 40 years to manage resistance to chemicals commonly used to spray homes and protect people from malaria.
- We are leading the world's largest HIV self-testing campaign to get more people aware of their status so they can be linked to care if needed.



HOW WE WORK

Unitaid identifies the most promising, close-to-market products that offer innovative health solutions; analyses the roadblocks that stand in the way of these innovations being adopted and used at scale; and removes them one by one. We look for partners to implement our programs in a competitive and transparent process, choosing only the very best proposals.

Our projects increase access to health innovations by, for example, establishing the added public health value of new products, reducing prices, supporting demand, and developing better versions that are adapted to people's needs.




WHO PAYS FOR IT?

Unitaid has received close to \$US 3 billion in contributions from donors since its establishment in 2006.

The main contributors are France, United Kingdom, Brazil, Norway, Chile, South Korea, Mauritius, Madagascar, Spain and Bill and Melinda Gates Foundation.

A key source of income is innovative financing, specifically the solidarity levy on airline tickets implemented by France, which was later adopted by a number of other countries (including Cameroon, Chile, Congo, Guinea, Madagascar, Mali, Mauritius, Niger, and the Republic of Korea).



TEN YEARS AND COUNTING

For more than a decade, Unitaid has been increasing access to health innovations by connecting the people who develops new products with those in charge of delivering, and using, them at scale. Unitaid is now shifting towards a more integrated approach to global health, cutting across diseases to strengthen health systems as a whole. With new projects in the pipeline, Unitaid will continue to invest in solutions for major diseases for years to come.